Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Stock-based compensation expense | 23,438 | 23,308 |
| Amortization of intangible asset | 1,572 | 1,572 |
| Amortization of debt discount | 159 | 667 |
| Depreciation | 116 | 149 |
| Loss in fair value of contingent consideration | 590 | 1,512 |
| Gain from lease modification | — | (2,250) |
| Non-cash lease expense | 844 | 609 |
| Right-of-use asset amortization for finance lease | 679 | 412 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's D&A?
- Axsome Therapeutics (AXSM) reported D&A of $116K in Q1 2026.
- How has Axsome Therapeutics's D&A changed year-over-year?
- Axsome Therapeutics's D&A decreased by 22.1% year-over-year, from $149K to $116K.
- What is the long-term trend for Axsome Therapeutics's D&A?
- Over 4 years (2021 to 2025), Axsome Therapeutics's D&A has grown at a 60.4% compound annual growth rate (CAGR), from $76K to $503K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Axsome Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude